Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16309201 | 0.88 | CAMK2D (0.44) | CAMK2DTNK2SRCRIPK2ACVR1 | |
| SCHEMBL15281139 | 0.80 | TNK2 (0.44) | CAMK2DTNK2SRCRIPK2ACVR1 | |
| SCHEMBL15281043 | 0.79 | CAMK2D (0.44) | CAMK2DTNK2SRCRIPK2ACVR1 | |
| SCHEMBL13553920 | 0.78 | CAMK2D (0.43) | CAMK2DTNK2SRCRIPK2ACVR1 | |
| SCHEMBL15041484 | 0.77 | FGFR1 (0.44) | CAMK2DTNK2SRCRIPK2ACVR1 | |
| SCHEMBL15281078 | 0.77 | CDK4 (0.37) | AXLFGFR1FGFR2WEE1 | |
| SCHEMBL15041481 | 0.77 | CAMK2D (0.43) | CAMK2DTNK2SRCRIPK2ACVR1 | |
| SCHEMBL15035795 | 0.76 | PKN1 (0.55) | TNK2SRCRIPK2ACVR1NOD2 | |
| SCHEMBL15041673 | 0.76 | TNK2 (0.42) | TNK2SRCRIPK2ACVR1NOD2 | |
| SCHEMBL14681967 | 0.75 | PAK3 (0.45) | CAMK2DTNK2SRCRIPK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CAMK2D 469/4885TNK2 7/4885SRC 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.